Full Text of PDF (803k)
Article in Japanese
Abstract
Case Report
Drug-induced lung injury due to niraparib: a case report
Toshiyuki Yonezawaa Saori Miyaraa Noriko Moritab Akihiko Wakatsukib Satoru Itoa
aDepartment of Respiratory Medicine and Allergology, Aichi Medical University
bDepartment of Obstetrics and Gynecology, Aichi Medical University
ABSTRACT
An 80-year-old woman was treated with niraparib, a poly ADP-ribose polymerase (PARP) inhibitor for stage IIIc ovarian cancer after surgery and adjuvant chemotherapy. Five months after starting to take niraparib, she was admitted to our hospital due to ground-glass opacities on chest computed tomography (CT). We diagnosed drug-induced lung injury due to niraparib based on the increased lymphocytes in the bronchoalveolar lavage fluid and the clinical course. Her condition became worse after discontinuation of niraparib alone but was improved by corticosteroid therapy. Because PARP inhibitors have been widely used for various malignancies, we should keep in mind the possibility of drug-induced lung injury.
KEYWORDS
Niraparib Poly ADP-ribose polymerase (PARP) inhibitor Drug-induced lung injury Drug lymphocyte stimulation test (DLST)
Received 31 Jul 2023 ／ Accepted 25 Sep 2023
AJRS, 13(1): 28-32, 2024
Copyright © The Japanese Respiratory Society All Rights Reserved.